Literature DB >> 12920161

Single nucleotide polymorphisms of the human cyp2a13 gene: evidence for a null allele.

Xiuling Zhang1, Ying Chen, Yiqin Liu, Xiang Ren, Qing-Yu Zhang, Michele Caggana, Xinxin Ding.   

Abstract

Human CYP2A13 is believed to be important in the metabolic activation of tobacco-specific nitrosamines in the respiratory tract; therefore, genetic polymorphisms of the CYP2A13 gene may be associated with interindividual differences in the risks of tobacco-related tumorigenesis. Our earlier studies identified a frequent single nucleotide polymorphism in CYP2A13 exon 5, Arg257Cys, which led to an approximate 50% decrease in metabolic activities. In the present study, three additional coding region mutations (Arg25Gln, Arg101Stop, and Asp158Glu) and several mutations in the introns and flanking regions were identified in a Chinese patient population. Of particular interest is the Arg101Stop mutation, which was due to a C > T change in exon 2. Thus, individuals homozygous for this nonsense mutation would not have a functional CYP2A13 protein and, therefore, might have reduced sensitivity to xenobiotic toxicity resulting from CYP2A13-mediated metabolic activation in the respiratory tract. The frequencies of the coding region mutations were further examined using random samples of white, black, Hispanic, and Asian newborns from New York. The frequency of the Arg25Gln mutation in Asian newborns (9.6%) was very similar to that found in the Chinese population (10.9%). On the other hand, the Arg101Stop mutation was not detected in 136 newborn samples examined (23 white, 21 black, 19 Hispanic, and 73 Asian), suggesting that this mutation may be unique for the Chinese patient population. Haplotype analysis indicated that the Arg25Gln and Arg257Cys mutations are parts of a common haplotype. However, an additional haplotype that consists of the 25Gln but not the 257Cys allele was also identified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920161     DOI: 10.1124/dmd.31.9.1081

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.

Authors:  Jaime D'Agostino; Xiuling Zhang; Hong Wu; Guoyu Ling; Suping Wang; Qing-Yu Zhang; Fucai Liu; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2008-07-31       Impact factor: 3.922

2.  Conversion events in gene clusters.

Authors:  Giltae Song; Chih-Hao Hsu; Cathy Riemer; Yu Zhang; Hie Lim Kim; Federico Hoffmann; Louxin Zhang; Ross C Hardison; Eric D Green; Webb Miller
Journal:  BMC Evol Biol       Date:  2011-07-28       Impact factor: 3.260

3.  Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese population.

Authors:  Ju-Hong Jiang; Wei-Hua Jia; Han-Kui Chen; Bing-Jian Feng; Hai-De Qin; Zhi-Gang Pan; Guo-Ping Shen; Li-Xi Huang; Qi-Sheng Feng; Li-Zhen Chen; Dong-Xin Lin; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2004-06-29       Impact factor: 5.531

4.  HapMap-based study: CYP2A13 may be a potential key metabolic enzyme gene in the carcinogenesis of lung cancer in non-smokers.

Authors:  Feng Hua; Yonglu Guo; Qiang Sun; Leizhou Yang; Fang Gao
Journal:  Thorac Cancer       Date:  2019-02-26       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.